Eustace Riley, MD
Family Medicine · Hodges, SCNPI 1639163058
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 660 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 46 manufacturers, the largest accounting for just 10.6% — the pattern of someone who eats at a lot of different presentations. Among family medicine clinicians in SC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 660 payments — averaging $14.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Lilly USA, LLC$914
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$852
- AstraZeneca$731
- Boehringer Ingelheim$651
- Novo Nordisk$644
- plus $5K from 40 others
Across 42 payments — averaging $2316.80 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$90K
- AstraZeneca$7K
What the payments were for
- Food & beverage$9,664100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$9,664 in reported general payments places this provider in the 95th percentile of 2,153 family medicine providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JanuviaSitagliptin Phosphate | 34 | $40,404 |
| EliquisApixaban | 36 | $34,876 |
| OzempicSemaglutide | 33 | $30,773 |
| TrulicityDulaglutide | 29 | $26,609 |
| Tresiba Flextouch U-200Insulin Degludec | 38 | $26,031 |
| FarxigaDapagliflozin Propanediol | 22 | $21,863 |
| JardianceEmpagliflozin | 22 | $21,402 |
| VraylarCariprazine Hcl | 11 | $18,144 |
| MyrbetriqMirabegron | 22 | $14,790 |
| XareltoRivaroxaban | 15 | $14,222 |
| Tresiba Flextouch U-100Insulin Degludec | 21 | $12,386 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 15 | $10,884 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 13 | $7,473 |
| SteglatroErtugliflozin Pidolate | 16 | $7,247 |
| Dexlansoprazole DrDexlansoprazole | 17 | $5,791 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| MerckJanuvia, Steglatro | $311 | $47,65150 claims |
| PfizerEliquis | $621 | $34,87636 claims |
| Novo NordiskOzempic | $644 | $30,77333 claims |
| Lilly USA, LLCTrulicity | $914 | $26,60929 claims |
| AstraZenecaFarxiga | $731 | $21,86322 claims |
| Boehringer IngelheimJardiance | $651 | $21,40222 claims |
| AbbVieVraylar, Synthroid | $1,027 | $20,02955 claims |
| Astellas Pharma US IncMyrbetriq | $37 | $14,79022 claims |
| Johnson & JohnsonXarelto | $62 | $14,22215 claims |
| GSKTrelegy Ellipta | $412 | $10,88415 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,153 family medicine providers in South Carolina.
Other family medicine in Hodges
- Stephen BruntonWinnsboro$1.3M
- Richard WilkesMt Pleasant$216K
- Andrew MartinColumbia$205K
- Ada StewartColumbia$186K
- Jeffrey BroderNorth Augusta$140K
- Terry NagelColumbia$112K
- Katherine JohnsonGreenwood$80K
- Scott SmithMount Pleasant$68K
- Jennifer StolinSummerville$59K
- Nicholas PenningsNorth Myrtle Beach$55K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.